Why is "PD-L1 inhibitor" trending?

Search Interest Perspective

• Correction: Discovery of novel disulfide-containing PD-1/PD-L1 inhibitor with in vivo influenza therapeutic efficacy - Nature
• Benmelstobart Plus Anlotinib in First-Line Treatment for PD-L1–Positive Advanced NSCLC - The ASCO Post
• Experience With Subcutaneous PD-L1 Inhibitor - OncLive
• New dimensions of PD-1/PD-L1 inhibitor combination therapy in cancer treatment: current advances and future perspectives - Frontiers
• Tarlatamab, PD-L1 Inhibitor Combo Shows Promise in 1L Maintenance for ES-SCLC - AJMC
• Atezolizumab plus a TIGIT inhibitor fails to demonstrate superiority to standard of care in NSCLC - ESMO Daily Reporter
• Sacituzumab Govitecan Improves PFS in 1L PD-1/PD-L1 Inhibitor Ineligible mTNBC - CancerNetwork
• FDA clears Imfinzi combo for 'blockbuster' perioperative gastric cancer setting - FirstWord Pharma
• OmRx Oncology begins Phase II trial of oral PD-L1 inhibitor for NSCLC - Clinical Trials Arena
• Envafolimab Receives FDA Orphan Drug Designation for Gastric and Gastroesophageal Junction Cancer - Oncodaily
• Discovery of novel disulfide-containing PD-1/PD-L1 inhibitor with in vivo influenza therapeutic efficacy - Nature
• In Extensive-Stage Small Cell Lung Cancer Novel Maintenance Regimen Boosts Overall Survival - The ASCO Post
• Evaluation of warning strategies for paraneoplastic neurological syndromes associated with PD-1/PD-L1 inhibitors - Frontiers
• Clinical characteristics and comparative analysis of PD-1/PD-L1 inhibitor-induced pituitary dysfunction versus other pituitary disorders - Nature
• PD-L1 Plus CTLA-4 Inhibition for Renal Cell Carcinoma Following Resection: RAMPART - The ASCO Post
• Impact of the PD-1/PD-L1 inhibitor SCL-1 on MDA-MB231 tumor growth in a humanized MHC-double knockout NOG mouse model - Nature
• Final Analysis Supports Use of Durvalumab Plus BCG Infusions in High-Risk Non–Muscle-Invasive Bladder Cancer - The ASCO Post
• A study on adverse drug events of PD-1/PD-L1 inhibitors in lung cancer treatment: a decade-long data mining - Nature
• Computational identification and evaluation of novel PD-L1 inhibitors for cancer immunotherapy - Nature
• Anti PD-L1 immunotherapy alters macrophage phenotypes via EGR1 and HSP90AB1 supported by integrated methodologies - Nature
• PD-1 and PD-L1 Inhibitor Market to Hit USD 62.23 Bn in 2025 Amid Rising Cancer Burden - BioSpace
• FDA Approves Wearable TTFields Treatment for Patients With Metastatic NSCLC - Docwire News
• Late-stage study failure for AstraZeneca's ATR inhibitor ceralasertib in lung cancer - FirstWord Pharma
• 'Unprecedented' Survival Seen With Maintenance Tarlatamab for SCLC in Early Study - MedPage Today
• Case Report: Immune-related eruptive keratoacanthoma with fungal coinfection under PD-1 inhibitor therapy: a diagnostic and therapeutic challenge - Frontiers
• OmRx Oncology Initiates Phase 2 Trial of Oral PD-L1 Inhibitor OX-4224 in NSCLC - BioSpace
• ASCO25 readout roundup: PD-(L)1 inhibitors from Roche and BMS, plus AstraZeneca's oral SERD - FirstWord Pharma
• Benmelstobart With/Without Anlotinib Improves PFS in Stage III NSCLC - Targeted Oncology
• BMS says subcutaneous version of Opdivo gets EU nod - FirstWord Pharma
• Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC) - Business Wire
• Roche, diagnostic partner tout biomarker-driven bladder cancer win for Tecentriq - Fierce Pharma
• RNF8 enhances the sensitivity of PD-L1 inhibitor against melanoma through ubiquitination of galectin-3 in stroma - Nature
• Addition of PD-L1 inhibitor may improve outcomes in neoadjuvant therapy for esophageal cancer - 2 Minute Medicine
• Promising outcomes of the PD-L1 inhibitor Socazolimab in recurrent and metastatic cervical cancer: a case report - Frontiers
• Mechanistic insights into lethal hyper progressive disease induced by PD-L1 inhibitor in metastatic urothelial carcinoma - Nature
• Metabolic remodeling by the PD-L1 inhibitor BMS-202 significantly inhibits cell malignancy in human glioblastoma - Nature
• Analysis of PD-1 and PD-L1 Inhibitor Systematic Reviews - Docwire News
• Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer - Nature
• Progress of research on PD-L1 inhibitor adebrelimab usage in malignant tumors - Frontiers
• Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice - Frontiers
• PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas - Frontiers
• Tumor-specific delivery of clickable inhibitor for PD-L1 degradation and mitigating resistance of radioimmunotherapy - Science | AAAS
• FDA Approves Atezolizumab and Hyaluronidase-tqjs (Tecentriq Hybreza) for Multiple Cancers - Oncology News Central
• Case report: Significant response to PD-L1 inhibitor after resistance to PD-1 inhibitor in an advanced alpha-fetoprotein-positive gastric cancer - Frontiers
• Arbutus announces FDA clinical hold on IND application for AB-101, an oral PD-L1 inhibitor - European AIDS Treatment Group
• Roche’s injectable PD-L1 inhibitor granted FDA approval for multiple cancer types - PMLiVE
• Enfortumab Vedotin-ejfv After PD-1 or PD-L1 Inhibitor Therapy for Cisplatin-Ineligible Patients With Advanced Urothelial Carcinoma - The ASCO Post
• Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis - Frontiers
• A retrospective study on the efficacy and safety of Envafolimab, a PD-L1 inhibitor, in the treatment of advanced malignant solid tumors - Frontiers
• FDA accepted PD-L1 inhibitor durvalumab for the treatment of endometrial cancer - News-Medical
• The miRNA and PD-1/PD-L1 signaling axis: an arsenal of immunotherapeutic targets against lung cancer - Nature
• Design of a protease‐activated PD‐L1 inhibitor - Goudy - 2023 - Protein Science - Wiley Online Library
• FDA Approves Belzutifan for Advanced RCC After PD-1 or PD-L1 Inhibition and a VEGF-TKI - AJMC
• Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges - Frontiers
• Tracon winds down weeks after world's first injectable PD-L1 inhibitor stumbles in phase 2 - Fierce Biotech
• Gilead details discovery of GS-4224, a potent PD-L1 inhibitor for cancer - BioWorld MedTech
• Case Report: Acute Myocarditis Due to PD-L1 Inhibitor Durvalumab Monotherapy in a Patient With Lung Squamous Cell Carcinoma - Frontiers
• PD-L1 Inhibitors for the Treatment of Extensive-Stage Small Cell Lung Cancer - cancertherapyadvisor.com
• Atezolizumab, a PD-L1 Inhibitor: An Association of Bleeding Gastric Ulcer With Its Use - Cureus
• FDA Approves Tumor Treating Fields Device (Optune Lua) for Metastatic NSCLC - Oncology News Central
• A Novel Type of PD-L1 Inhibitor rU1 snRNPA From Human-Derived Protein Scaffolds Library - Frontiers
• Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development - Frontiers
• Case report: A case of complete clinical response in a patient experiencing high microsatellite instability unresectable colon cancer being treated with a PD-L1 inhibitor after interstitial pneumonia - Frontiers
• An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses - Nature
• FDA Oks Optune Lua for Use With PD-1/PD-L1 Inhibitors in Metastatic NSCLC - Targeted Oncology
• BMS-202, a PD-1/PD-L1 inhibitor, decelerates the pro‑fibrotic effects of fibroblasts derived from scar tissues via ERK and TGFβ1/Smad signaling pathways - Wiley Online Library
• Dr Lau on Tarlatamab as Maintenance Therapy in Extensive-Stage SCLC - OncLive
• Unraveling the Efficacy of PD-1/PDL-1 Re-challenge in Kidney Cancer: CONTACT-03 Study - Toni K. Choueiri - UroToday
• A retrospective analysis of immune checkpoint inhibitors in patients with preexisting organ dysfunction - Wiley
• Two oral immune checkpoint inhibitors show preliminary efficacy and manageable safety in early trials - ESMO Daily Reporter
• FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy - OncLive
• Combining WEE1 inhibition with PD-L1 blockade shows promise in SCLC models - ESMO Daily Reporter
• PD-1 inhibition plus chemoradiotherapy is effective across ethnicities in locally advanced cervical cancer - ESMO Daily Reporter
• Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer - NEJM Evidence
• Immunotherapy With Cemiplimab-rwlc Yields Survival Benefit in Advanced Cervical Cancer - The ASCO Post
• Nanoparticle-enhanced PD-1/PD-L1 targeted combination therapy for triple negative breast cancer - Frontiers
• The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy - Frontiers
• Case Report: Replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma - Frontiers
• The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers - Frontiers
• High number of PD-1/L1 inhibitor trials in microsatellite stable colorectal cancer could signal future success for immunotherapy - Clinical Trials Arena
• Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature - Frontiers
• Advanced Melanoma: Lenvatinib Plus Pembrolizumab After Disease Progression on Anti–PD-1 Therapy - The ASCO Post
• In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction | Scientific Reports - Nature
• FDA Approves Tislelizumab-jsgr (Tevimbra) Combo for Gastric or Gastroesophageal Junction Cancer - Oncology News Central
• AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024 - PR Newswire
• Checkpoint Therapeutics takes on Merck's mighty Keytruda with FDA approval for Unloxcyt in skin cancer - Fierce Pharma
• Inosine enhances the efficacy of immune-checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study - Wiley Online Library
• Study Finds Durvalumab Plus Carboplatin and Paclitaxel Effective, Tolerable in Frail Patients With Head and Neck Cancer - The ASCO Post
• β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer - Frontiers
• Enfortumab vedotin impresses in post-immunotherapy bladder cancer - Urology Times
• 5-Year Survival Outcomes With Consolidation Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC - The ASCO Post
• Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature - Wiley
• From COPD to cancer: indacaterol’s unexpected role in combating NSCLC - Frontiers
• Pre-operative immunoradiation shows clinical benefit in patients with high-risk, early-stage breast cancer - ESMO Daily Reporter
• Results From the Preclinical Study of HLX43, a Potential FIC PD-L1-Targeting ADC Released at 2023 ESMO - 复宏汉霖
• NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer - PMLiVE
• New Agents for Post–PD-1 Failure, Promising Long-term Follow-up After Immunotherapy Data Propel Melanoma Field Forward - ASCO Daily News
• Incyte drops pair of PD-L1 drugs as part of 2nd pipeline clear-out this year - Fierce Biotech
• Neoadjuvant Durvalumab Improves Long-Term Outcomes in the GeparNuevo Trial - The ASCO Post
• Dual immunotherapy regimen shows early promise in urothelial carcinoma - Urology Times